The FTC ruled on April 3 that Illumina must divest itself of the cancer diagnostics firm Grail, a decision designed to promote competition in the multi-cancer early detection market by providing equal access to essential DNA sequencing technology.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.